SITE008-0432

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE008 (KOR) · Dr. Kim
consented 2023-08-18

AEs

Serious

Dropout signal

–

Adverse events

severe serious assessed

Grade 3 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-11-27 (study day 88); relationship: N; serious criteria: hospitalization

mild assessed

Grade 1 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2024-03-08 (study day 190); relationship: N

moderate assessed

Grade 2 Asthenia — outcome: RECOVERED/RESOLVED; onset 2024-03-26 (study day 208); relationship: not assessed

mild assessed

Grade 1 Constipation — outcome: RECOVERED/RESOLVED; onset 2024-03-29 (study day 211); relationship: not assessed

severe serious assessed

Grade 4 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2024-04-17 (study day 230); relationship: not assessed; serious criteria: life-threatening

severe serious assessed

Grade 4 Asthenia — outcome: RECOVERED/RESOLVED; onset 2024-05-29 (study day 272); relationship: not assessed; serious criteria: life-threatening

mild assessed

Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2024-08-29 (study day 364); relationship: not assessed

Data queries

No data queries.